In the aftermath of pharmaceutical giant Pfizer (NYSE: PFE ) failing in its repeated attempts to acquire European drug maker AstraZeneca (NYSE: AZN ) , investors may be wondering what’s next. After all, Pfizer’s enormous offer and seeming willingness to pay quite a premium to no avail has left a bit of egg on management’s face. In its post-Lipitor era, organic growth has been hard to come by. And, since taking new drugs all the way to market is an extremely costly and time-consuming effort, management probably feels the easiest way to get the growth it needs now is by buying up a rival company.
Hey, check out all the research scientist jobs. Post your resume today!
